anti-BCMA/CD38/CD3 trispecific antibody ISB 2001

A T-cell engager and trispecific antibody targeting the two tumor-associated antigens (TAAs) CD38 and human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon intravenous administration, anti-BCMA/CD38/CD3 trispecific antibody ISB 2001 simultaneously targets and binds to CD38 and BCMA expressed on tumor cells, and CD3 expressed on T cells. The resulting cross-linkage activates and redirects CTLs to CD38- and BCMA-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Targeting both BCMA and CD38 increases binding and specificity to tumor cells, such as myeloma cells, and specifically increases death in tumors cells co-expressing CD38 and BCMA.